• Test That Measures MicroRNA in Blood Is Good Way to Diagnose ALS, Study Shows
  • Cytokinetics Ends Tirasemtiv Program After Potential ALS Therapy Fails at Trial Goals
  • C.H.A.R.M. Through the Holidays
  • Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US
  • FDA-Approved Schizophrenia Medicine Orap Appears to Benefit ALS Patients, Canadian Study Reports
  • Muscular Dystrophy Association Awards $3.5M in New Research Grants
  • Neurimmune and Ono Partner to Create Possible ALS Treatments Based on Antibodies
  • End-of-life Care Important in Neurodegenerative Diseases But Can Be Lacking, Study Finds
  • Phase 2 COMMEND Trial Enrolls ALS Participants After Flex Reports Positive Topline Results
  • Cytokinetics to Release Phase 3 Tirasemtiv Data Next Month in Support of Likely FDA Filing, EVP Says in Interview
  • Acts of Kindness are Meaningful
  • ALS-linked Protein Accelerates Nerve-cell Deterioration Seen in Aging, Study Reports